205 related articles for article (PubMed ID: 37366913)
21. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
[TBL] [Abstract][Full Text] [Related]
22. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
23. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
[TBL] [Abstract][Full Text] [Related]
24. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
Chen KH; Lee CY; Wu FL; Yang CY; Yeh CC; Hu RH; Tsai MK
J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
[TBL] [Abstract][Full Text] [Related]
25. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients.
Arnold R; Pussell BA; Pianta TJ; Lin CS; Kiernan MC; Krishnan AV
Am J Transplant; 2013 Sep; 13(9):2426-32. PubMed ID: 23841745
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study.
Préterre J; Visentin J; Saint Cricq M; Kaminski H; Del Bello A; Prezelin-Reydit M; Merville P; Kamar N; Couzi L
Clin Transplant; 2021 Mar; 35(3):e14207. PubMed ID: 33369772
[TBL] [Abstract][Full Text] [Related]
27. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
28. Risk Factors for Melanoma in Renal Transplant Recipients.
Ascha M; Ascha MS; Tanenbaum J; Bordeaux JS
JAMA Dermatol; 2017 Nov; 153(11):1130-1136. PubMed ID: 28746700
[TBL] [Abstract][Full Text] [Related]
29. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
30. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
31. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.
Hong T; Zhang M; Fan J
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607
[TBL] [Abstract][Full Text] [Related]
32. [Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital].
Rodríguez-Acosta ED; Calva-Mercado JJ; Alberú-Gómez J; Vilatoba-Chapa M; Domínguez-Cherit J
Gac Med Mex; 2015; 151(1):20-6. PubMed ID: 25739480
[TBL] [Abstract][Full Text] [Related]
33. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
35. Genetics and nonmelanoma skin cancer in kidney transplant recipients.
Burke MT; Isbel N; Barraclough KA; Jung JW; Wells JW; Staatz CE
Pharmacogenomics; 2015 Jan; 16(2):161-72. PubMed ID: 25616102
[TBL] [Abstract][Full Text] [Related]
36. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study.
Ying T; Wong G; Lim W; Kanellis J; Pilmore H; Campbell S; Masterson R; Walker R; O'Connell P; Russ G; Chadban S
Am J Transplant; 2018 Dec; 18(12):2977-2986. PubMed ID: 29802791
[TBL] [Abstract][Full Text] [Related]
37. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
[TBL] [Abstract][Full Text] [Related]
38. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2012 Mar; (3):CD008852. PubMed ID: 22419339
[TBL] [Abstract][Full Text] [Related]
39. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
40. Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland.
Thet Z; Lam AK; Ng SK; Aung SY; Han T; Ranganathan D; Newsham S; Borg J; Pepito C; Khoo TK
Aust J Rural Health; 2024 Apr; 32(2):249-262. PubMed ID: 38646861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
